QLGN - Qualigen Therapeutics, Inc. Stock Price, Fair Value and News

$3.87+0.01 (+0.26%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

QLGN Price Action

Last 7 days

-6.1%

Last 30 days

-57.7%

Last 90 days

-63.1%

Trailing 12 Months

-88.8%

QLGN RSI Chart

QLGN Valuation

Market Cap

2.8M

Price/Earnings (Trailing)

-0.38

Price/Sales (Trailing)

0.5

EV/EBITDA

-0.31

Price/Free Cashflow

-0.29

QLGN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

QLGN Fundamentals

QLGN Revenue

Revenue (TTM)

5.3M

QLGN Earnings

Earnings (TTM)

-7.5M

Earnings Growth (Yr)

51.45%

Earnings Growth (Qtr)

-13.8%

QLGN Profitability

EBT Margin

-147.89%

Return on Equity

351.84%

Return on Assets

-325.65%

Free Cashflow Yield

-342.39%

QLGN Investor Care

Shares Dilution (1Y)

610.70%

Diluted EPS (TTM)

-85.88

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	5.3M	0	0
2022	4.5M	4.8M	0	0
2021	4.7M	5.0M	5.3M	5.7M
2020	5.5M	4.9M	4.5M	4.2M
2019	172.2K	1.7M	2.8M	4.2M
2018	58.3K	73.7K	86.8K	126.8K
2017	48.3K	37.9K	28.8K	40.2K
2016	59.2K	73.8K	68.2K	60.9K
2015	0	0	0	40.9K

Get all data in R, Python etc through our Historical Stock Data APIs

About Qualigen Therapeutics, Inc.

Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

CEO	Mr. Michael S. Poirier
WEBSITE	qualigeninc.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	31

Qualigen Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Qualigen Therapeutics, Inc.? What does QLGN stand for in stocks?

QLGN is the stock ticker symbol of Qualigen Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Qualigen Therapeutics, Inc. (QLGN)?

As of Wed Nov 20 2024, market cap of Qualigen Therapeutics, Inc. is 2.85 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of QLGN stock?

You can check QLGN's fair value in chart for subscribers.

Is Qualigen Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether QLGN is over valued or under valued. Whether Qualigen Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Qualigen Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for QLGN.

What is Qualigen Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Nov 20 2024, QLGN's PE ratio (Price to Earnings) is -0.38 and Price to Sales (PS) ratio is 0.5. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. QLGN PE ratio will change depending on the future growth rate expectations of investors.